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Conclusions. This study demonstrates that alkaline therapyBone histology and bone mineral density after correction of
corrects abnormal bone cell function and elevates bone mineralacidosis in distal renal tubular acidosis.
density in dRTA patients, indicating the causal role of acidosisBackground. The association between chronic metabolic ac-
in the alterations of bone cell functions and reduction in boneidosis and alterations in bone cell functions has been demon-
mineral density. Parathyroid gland activity also may be involvedstrated in vitro and in animal studies. However, the causal role
in the adaptation of the body to chronic metabolic acidosis.of acidosis and the effects of alkaline therapy on bone histology
and bone mineral density in chronic metabolic acidosis have
never been systematically demonstrated in humans. This study
was conducted to examine the alterations in bone mineral density Distal renal tubular acidosis (dRTA) is a condition
and bone histology before and after correction of acidosis among associated with impaired renal acid excretion, resulting
patients with distal renal tubular acidosis (dRTA) in accumulation of acid in the body. The disease is associ-
Methods. Correction of metabolic acidosis by potassium ci- ated with growth retardation [1], skeletal pain, abnormaltrate was done in non-azotemic dRTA patients, 6 females and
bone metabolism, and pathologic fractures [2, 3]. Our4 males, who had never received long-term alkaline therapy
previous study on bone mineral metabolism in patientsbefore enrolling into this study. Blood chemistries, serum intact
with dRTA demonstrated significant suppression in bothparathyroid hormone, and 24-hour urine collection for the de-
termination of urinary calcium, phosphate, sodium, potassium, bone formation and bone resorption in association with
bone mineral density determination, and transiliac bone biopsy mild elevation in osteoid volume [3]. Most dRTA patients
were done in all patients at baseline and after one year of also had a marked reduction in bone mineral density of
potassium citrate therapy. spine and hip [3]. A putative causal role of metabolicResults. Significant elevations in serum bicarbonate (16.5 
acidosis in the development of skeletal growth retardation3.0 vs. 24.6  2.8 mEq/L, P  0.05) and urinary potassium
is supported by the fact that alkaline therapy normalizedexcretion (35.2  7.9 vs. 55.4 3.5 mEq/L, P  0.05) were
observed after potassium citrate therapy. No significant alter- bone growth in children with dRTA [1]. In vitro and
ations in other serum and urine electrolytes were found after animal studies suggest that the abnormal bone metabo-
the therapy. Serum intact parathyroid hormone level was also lism in chronic metabolic acidosis results mainly from
significantly elevated after one year of treatment (12.8  7.3 both acidosis-induced physicochemical mineral dissolu-vs. 26.2  8.7 pg/mL, P  0.05). Bone formation rate was
tion and later through alterations in bone cell functionsignificantly suppressed at baseline and was normalized by the
[4–8]. Limited human studies on the effects of alkalinetreatment (0.02  0.02 vs. 0.06  0.03 m3/m2/day, P  0.05).
therapy in the correction of the abnormal bone histologyThere were non-significant elevations in trabecular bone vol-
ume, osteoblastic and osteoclastic numbers. Bone mineral den- and bone mineral density are available. Most studies
sities in dRTA patients were also significantly decreased below were case reports and provided no information on cell-
normal values in most studied areas at baseline and were sig- mediated-response to the alkaline-induced correction of
nificantly elevated at the trochanter of femur (0.677  0.136 metabolic acidosis [9, 10]. The aim of this subsequentvs. 0.748  0.144 g/c m2, P  0.05) and total femur (0.898 
study, therefore, was to examine the alteration in bone0.166 vs. 0.976  0.154 g/c m2, P  0.05) after the treatment.
histology and bone mineral density after correction of
chronic metabolic acidosis in dRTA patients.
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Table 1. Patient characteristics and presentations
Urine
Age Height Weight BMI Blood/urine ammonium Durationb
No. year Sex cm kg kg/m2 pHa meq/day months Presentations
1 21 F 151 39 17.10 7.32/6.5 24 60 Muscle weakness, pseudofracture
2 42 F 147 35 16.29 7.29/6.0 29 120 Muscle weakness, renal stone
3 35 M 160 53 20.70 7.32/6.5 34 60 Muscle weakness
4 16 F 157 44 17.85 7.31/7.0 36 8 Muscle weakness
5 35 F 145 46.7 22.21 7.30/6.0 29 18 Muscle weakness
6 30 M 170 65 22.50 7.29/6.2 30 36 Muscle weakness
7 50 F 146 50 31.49 7.31/6.8 30 60 Muscle weakness
8 42 M 158 53 21.23 7.28/6.4 32 120 Muscle weakness
9 20 M 136 32.3 17.46 7.30/6.9 24 144 Fracture lt. femur, renal stone
10 25 F 148 39.5 18.03 7.32/6.5 31 24 Muscle weakness, nephrocalcinosis
Mean 31.6 — 151.8 45.7 20.5 7.3/6.5 29.9 65
SD 11.1 9.6 9.9 4.5 0.01/0.35 3.8 47.5 —
BMI is body mass index.
a Determined at the time of presentation
b Duration of symptom
where a very high incidence of dRTA has been reported fashion, using either 15 mEq or one package increment,
until the desired serum bicarbonate level was reached.[11]. All subjects were a subgroup of the dRTA patients
reported in our previous study on bone mineral density For patients who had an adequate response to the initial
dosage of potassium citrate, there was no reduction inand histology [3], who remained in the province through-
out the study. However, only ten patients, four males the dosage below 60 mEq in order to ensure an adequate
supply of potassium citrate throughout the study. Theand six females, agreed to participate in our current study
and completed the study protocol. The patient character- compliance was checked by package count and determi-
nation of serum electrolytes. Follow-up was done at two-istics and presentations of this subgroup, summarized in
Table 1, were not different from the entire study popula- month intervals. No medication that might affect calcium
and bone metabolism, for example diuretics, vitamin D,tion reported previously. All patients had received only
short-term treatment for their symptoms before enroll- estrogen, bisphosphonate, and calcium supplement, was
allowed throughout the study. After one year of alkalinement into this study. Patient characteristics, clinical pre-
sentations, and approximated duration of the disease for therapy, all the investigations done at baseline were re-
peated. The second transiliac crest bone biopsy was doneindividual dRTA patient are presented in Table 1. The
total energy intake in this group of dRTA patients was in the opposite side to the first biopsy. The study was
done while the patients were on their own choice of diet1852.8 392.5 kcal/day, carbohydrate 380.52 85.9 g/day
(82.1 18.6% of total calories), protein 55.2 13.4 g/day and the urine collections were done in an outpatient set-
ting. There was no intention to modify their normal life(11.9  2.8% of total calories), and fat 14.1  8.4
g/day (6.1  3.6% of total calories). The calcium intake activity and diet throughout the study.
was 9.45  4 mmol/day.
Biochemical analysis
Study protocol Blood samples were taken from dRTA patients after
an overnight fast at the time of bone biopsy. SerumBaseline biochemical parameters, including creati-
nine, electrolytes, calcium, phosphorus, serum intact electrolytes, calcium and phosphate were determined
by using a Technicon Auto Analyzer. Serum iPTH wasparathyroid hormone (iPTH), and 24-hour collection of
urine for the determination of sodium, potassium, cal- determined by an immunoradiometric assay (ELSA-PTH;
CIS BioInternational, GIF-sur-Yvette Cedex, France).cium, phosphate, and creatinine were obtained in all
patients. Baseline bone mineral density of the spine and The normal value for iPTH was 10 to 60 pg/mL. Twenty-
four–hour urine collections for sodium, potassium, cal-femur, radiography of the lumbar spine and pelvis, and
transiliac crest bone biopsy were determined also in all cium, phosphate, and creatinine were obtained at the
time of bone biopsy. Hypercalciuria on low calcium dietspatients. Then, all of the patients were treated with 60
mEq/day of potassium citrate in two divided doses to (3.75 to 7.5 mmol/day of elemental calcium) was defined
as a urinary calcium excretion 4.75 mmol/day in eitherkeep the serum bicarbonate above 20 mmol/L through-
out the study. Potassium citrate was provided in powder sex. Hypercalciuria on normal to high calcium diets (12–25
mmol/day of elemental calcium) was defined as a urinaryform and in a 15-mEq package. For patients who initially
failed to achieve the target serum bicarbonate level, the calcium excretion6.0 mmol/day (female) or6.5 mmol/
day (male); or 0.1 mmol/kg (either sex) [2, 12].dosages of potassium citrate were increased in a stepwise
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Table 2. Blood (per liter) and urine (per day) chemistries for dRTA patients
Baseline At 6 months After treatment Normalb
Serum Urine Serum Urine Serum Urine Serum Urine
Creatinine lmol 10836 690120 9927 730150 9918 700100 91.538 106171
Sodium mmol 138.81.9 113.727.9 1402.5 12030 141.62.6 113.226 13851 110.690
Potassium mmol 3.40.8 35.27.9 4.00.5a 6020a 4.10.4a 55.435a 4.10.1 20.84.7
Chloride mmol 115.8 3.4 — 1093.2 — 108.74.3 — 1052.5 —
Bicarbonate mmol 16.53.0 — 24.03.0 — 24.62.8a — 251.5 —
Calcium mmol 2.10.1 2.61.7 2.10.3 3.01.12 2.30.2 2.91.7 2.30.5 2.751.7
Phosphate mmol 0.80.2 10.64.5 1.10.2a 9.63.5 1.10.2a 10.22.9 1.20.1 10.65.5
iPTH pg/mL 12.87.3 — — — 26.28.7a — — —
a Significant difference when compared to the corresponding baseline value (P  0.05)
b Data obtained from the 28 normal farmers who were permanent residents of Khon Kaen province
Bone mineral density values for normal histomorphometric parameters were
obtained from 17 normal Thai adults without bone dis-Bone mineral density (BMD; g/cm2) was determined at
ease, eight men and nine women, age 35.1  2.8 yearsvertebral (L2-L4), femoral neck, trochanter, and Wards’
(range 19 to 58), height 1.61  0.06 m, weight 59.2 triangle by dual energy x-ray absorptiometry (Lunar Ex-
7.8 kg, BMI 22.7  2.6 kg/m2.pert XL, Lunar Corp., USA). Precision of the BMD
The protocol of the study was approved by ethicalmeasurement in our laboratory at L2-L4, and neck of
committee for research involving human subjects of thefemur was 1.2 and 0.6%, respectively. The bone density
Department of Medicine, Faculty of Medicine, at Khondata also are presented as the Z score, in order to relate
Kaen University. Written informed consents were ob-to age-and sex-matched normal values for the Asian
tained from all subjects.population. The control value of BMD was obtained
from 28 normal farmers who were permanent residents Statistical analysis
of Khon Kaen province: age 32.9  11.2 years, weight
Results are presented as mean  SD. The paired and54.3  8.3 kg, height 1.55  0.05 m, body mass index
unpaired Student t test was used to compare group means(BMI) 22.7  3.1 kg/m2, male:female ratio 22:6.
as appropriate. There was a significant difference if the
P value was less than 0.05.Bone biopsy and bone histomorphometry
Transiliac crest bone samples were taken from the
anterior superior iliac spine after tetracycline double la- RESULTS
beling, using the same protocol reported previously [3]. Most patients had short stature and low body mass index
In brief, the bone specimens, 6 mm in diameter and 20 when compared to general Thai population (Table 1). Al-
to 30 mm in length, were fixed for 24 hours in 70% most all of the patients (9 of 10) suffered from muscle
ethanol, dehydrated, and embedded in methylmethacry- weakness, and three patients developed urinary tract
late. Undecalcified 6-micron thick sections were stained stones or nephrocalcinosis. Blood chemistries, serum
with modified Masson-Goldner trichrome stain [13], aurin iPTH levels, and 24-hour urinary excretion of sodium,
tricarboxylic acid stain (Aluminon) [14], Von-Kossa and potassium, calcium, and phosphate before and after po-
hematoxylin-eosin stain. If the specimen had a positive tassium citrate therapy are presented in Table 2. At
stain for aluminum, a further stain with Perls stain to baseline, all patients had hypokalemia, five patients had
exclude cross-reaction with iron deposit was done. Un- hypophosphatemia, but no patient had hypocalcemia.
stained sections 15-microns thick were prepared for flu- Serum iPTH levels were in the lower end of the normal
orescent light microscopy. All sections, both pre- and range. The urinary excretion of calcium and phosphate
post-potassium citrate therapy, were studied qualita- were relatively low. No patient had hypercalciuria at
tively and quantitatively for static and dynamic parame- baseline.
ters of bone formation and bone resorption by the same During potassium citrate therapy, all dRTA patients
pathologist and technician, who had no knowledge of could maintain their serum bicarbonate above 20 mmol/L
the patients’ clinical presentations and treatments. Histo- throughout the study with 60 to 90 mEq/day, or 1.65 
morphometric measurements were carried out with a 0.2 mEq/kg/day, of potassium citrate. Most patients re-
semiautomatic image analyzer (Osteomeasure; Osteo- ported a rapid improvement in their skeletal symptoms
metric Inc, Atlanta, USA). At least 30 different fields after initiation of the treatment. There was a dramatic
were analyzed for the same bone biopsy specimen. Histo- improvement in muscle strength in all dRTA patients
morphometric parameters are expressed according to after two to three months of therapy. After treatment,
serum potassium, bicarbonate, and phosphate levels wereParfitt et al’s standardized nomenclature [15]. Reference
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Table 3. Bone mineral density (g/cm2) of dRTA patients
dRTA patients
BMD Z-score
Normal
Area Baseline After treatment Baseline After treatment BMD
L2-L4 1.040.17 1.070.13 0.41.2 0.21.2 1.150.25
Total femur 0.900.17a 0.980.15b 0.11.1 0.40.9b 1.050.29
Neck 0.830.15a 0.890.10 0.10.9 0.030.8 1.000.25
Wards’ 0.670.17a 0.720.13 0.71.1 0.41.1 0.890.3
Trochanter 0.680.14a 0.750.14b 0.60.9 0.11.1b 0.810.27
P  0.05 compared to anormal controls or to bbaseline BMD in dRTA patients
Table 4. Baseline and after treatment bone histomorphometry in dRTA patients
dRTA
Histomorphometric parameters Baseline After treatment Reference values (range)
Bone volume (BV/TV) % 20.929.89 (15.63–25.56) 23.424.56 (16.98–28.0) 26.447.21 (12.72–36.88)
Osteoid volume (OV/TV) % 3.614.41a (0.17–13.03) 3.134.82a (0.20–13.90) 0.921.05 (0.2–3.06)
Osteoid surface (OS/BS) % 26.1723.44a (3.27–85.41) 24.9820.23a (7.12–75.67) 5.794.39 (0.30–15.86)
Osteoid thickness (O.th) lm 11.858.24 (4.43–29.95) 15.819.56 (8.22–33.78) 8.692.14 (5.53–15.87)
Osteoblastic surface (Ob.S/BS) % 1.190.88 (0–2.43) 1.792.01 (0.15–5.44) 2.61.1 (0.51–4.80)
Osteoclastic surface (Oc.S/BS) % 0.040.04 (0–0.08) 0.050.06 (0–1.16) 0.130.23 (0.01–0.59)
Osteoclast number (N.Oc/T.Ar)/mm2 0.120.12 (0–0.31) 0.110.15 (0–0.32) 0.240.31 (0.01–0.83)
Eroded surface (ES/BS) % 5.522.75 (1.78–9.71) 3.962.35 (1.69–7.94) 5.682.32 (2.08–10.06)
Mineral apprositional rate (MAR) lm/day 0.670.42a (0.16–1.26) 1.220.49b (0.42–1.86) 1.320.69 (0.48–2.94)
Bone formation ratec (BFR/BS) lm3/lm2/day 0.020.02a (0.001–0.19) 0.060.03b (0.006–0.21) 0.070.045 (0.001–0.167)
a Significant difference when compared to the corresponding normal value (P  0.05)
b Significant difference when compared to the corresponding baseline value (P  0.05)
c BFR/BS was calculated from the formula: BFR/BS  [(MS/BS)  MAR]/100, where MS/BS (mineralizing surface, %) was the extent of tetracycline labeled
surfaces as a percentage of total trabecular bone surface (double plus half single labeled surfaces)
significantly increased above the corresponding baseline normalized (Fig. 1). Trabecular bone volume, osteoid
thickness, osteoblastic and osteoclastic surfaces werevalues. There was no significant alteration in serum cal-
modestly elevated, but the differences were not signifi-cium level by the treatment. Urinary excretion of potas-
cant. Differences in other histomorphometric parame-sium and phosphate were significantly elevated, but there
ters also were not significant. No positive staining forwere no significant changes in the other urine constit-
aluminum was found in any of the bone specimens, eitheruents studied. Serum iPTH level was significantly ele-
before or after treatment. There was no correlation be-vated above the baseline value, but it was still within the
tween the histomorphometric parameters and serum bi-normal limit.
carbonate, serum potassium, or serum phosphate atBone mineral density at baseline and the end of the
baseline, as well as no correlation between the alterationsstudy period are shown in Table 3. The basal BMD
in histomorphometric parameters and the alterations invalues of dRTA patients were significantly lower than
the blood chemistries after treatment.those of normal controls in all studied areas (P  0.05)
except in the lumbar spine. After one year of alkaline
therapy, there were significant elevations in BMD of DISCUSSION
total femur and the trochanter of femur. The BMD in Potassium citrate therapy successfully corrected meta-
other studied areas also were elevated, but the differ- bolic acidosis by maintaining the serum bicarbonate level
ences were not statistically significant. above 20 mEq/L in our patients throughout the study.
Bone histomorphometric data before and after treat- The hypokalemia found initially in the majority of pa-
ment are presented in Table 4. At baseline there was tients also was corrected. After treatment, there was a
significant suppression in the bone formation rate (BFR), significant elevation in urinary excretion of potassium;
and elevations in osteoid volume and osteoid surface com- however, the increment in urinary potassium was lower
pared to the corresponding parameters in normal con- than expected. Since most of the patients were farmers
trols. There was no difference from normal control val- who spent most of their time in the field, excessive potas-
ues in the other histomorphometric parameters. After sium loss in the sweat might be an additional route of
potassium citrate therapy, BFR in dRTA patients was potassium loss from the body [16]. The mean value of
potassium loss among normal farmers in the northeastsignificantly elevated above the baseline value and was
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Fig. 1. Bone formation rate (A), bone volume (B), osteoid volume (C), and osteoid surface (D) for individual distal renal tubular acidosis (dRTA)
patients. The bone formation rate was markedly suppressed in dRTA patients. There was a significant elevation in bone formation rate after one
year of potassium citrate therapy in dRTA patients. The post-treatment values were within the lower limit of the normal range.
of Thailand was 11.5 mmol/day in summer and 7.4 mmol/ No patient was diagnosed with hypercalciuria at base-
line and a reduction in urinary excretion of calcium wasday in winter [17]. This amount of sweat potassium was
about half or a third of urinary potassium excretion in not observed after treatment. This finding is in contrast
to a few previous studies where hypercalciuria was in-the corresponding season. The discrepancy also might
result from a positive potassium balance in the body, as duced by acute metabolic acidosis [20–22]. The increase
in urinary calcium excretion after an acute acid loadfound in healthy men after taking a potassium bicarbon-
ate supplement [18]. Acute metabolic acidosis is accom- results mainly from bone resorption [23]. However, an
increase in bone resorption was not observed at baselinepanied by a loss of sodium and potassium from bone
surface [19]. Deposition of potassium together with car- in our patients diagnosed with long-standing metabolic
acidosis, which might differ in response from acute acido-bonate in bone may take place after the correction of
acidosis. There was no correlation between the dosage sis. Serum phosphate was significantly elevated by the
treatment, which might result from a reduction in frac-of potassium citrate and the baseline serum bicarbonate
level. However, potassium citrate was increased in a step- tional excretion of phosphate [24], secondary to the ef-
fect of potassium loading on renal phosphate transportwise fashion in our study and there was no intention of
finding a “threshold” dosage of potassium citrate. [25, 26] and/or the collection of chronic metabolic acido-
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sis [27, 28]. Although serum iPTH also was elevated by bone histomorphometry and serum bicarbonate or se-
the treatment, it was not associated with an elevation in rum phosphate, either the baseline values or after treat-
urinary excretion of phosphate. The collections of hypo- ment, was found in our study.
kalemia and acidosis may overcome the effect of the ele- Most in vitro or animal studies demonstrated that met-
vated serum iPTH on renal phosphate excretion in our abolic acidosis enhanced osteoclastic, but inhibited osteo-
dRTA patients. blastic activity [4, 6, 8]. This led to an uncertainty about
The concentration of serum 1,25-(OH)2-vitamin D was whether concurrent metabolic derangement or chronic
not determined in this study as it was unlikely for this metabolic acidosis contributed to the initial histologic
group of patients to be vitamin D deficient, as they typi- findings in our study. It is unknown whether the underly-
cally worked in sunny rice fields throughout the year ing cellular defect in dRTA is confined only to the renal
[29]. Previous studies also demonstrated that metabolic tubular cell or extends to other cell lines. If a proton
acidosis did not have a substantial impact on vitamin D pump defect affects both renal tubular cell and osteo-
metabolism in humans [30–32]. clast, metabolic acidosis may be unable to stimulate osteo-
Most of dRTA patients had a short stature based on clastic function during acidosis. After treatment, however,
the normal Thai standard. Previous studies [1, 33] and the bone formation rate was markedly elevated and nor-
our recent study in pediatric patients with dRTA [24] malized. The initial mineralization defect tended to im-
have demonstrated growth retardation. Correction of prove, as indicated by the modest reduction in both oste-
acidosis markedly improved the growth rate. The effect oid surface and volume after treatment. There was also
of metabolic acidosis on bone growth may be mediated, a tendency for the elevations in trabecular bone volume,
at least in part, through the reduction in IGF-1 response osteoblastic and osteoclastic activities after treatment.
to circulating growth hormone [34] as well as the resis- The improvement in bone histology supports the causal
tance of skeletal growth centers to growth hormone and role of acidosis in the alteration of bone histology found
IGF-1 [35]. However, we found no correlation between initially in dRTA patients. Other factors, for example
the height and the estimated age of onset of the disease the duration, age at onset, and the severity of the disor-
in our patients. der, also might influence the response to the treatment.
Bone mineral density in our patients also was mark- Our findings demonstrated suppression of parathyroid
edly reduced in various areas. The femur was more af- activity in chronic metabolic acidosis. Although the basal
fected than the lumbar spine. After alkaline therapy, there iPTH level was within the normal range, most of the
were significant elevations in BMD of total femur and measurements were close to the lower limit. This finding
trochanter of femur, suggesting the causal role of acidosis was consistent with the baseline low bone turnover in our
in the reduction of bone loss in dRTA patients. It should
dRTA patients and may explain the lack of hypercalciuria.be noted, however, that one year of alkaline therapy
After one year of alkaline therapy, the serum iPTH levelfailed to completely normalize the BMD in our patients
was significantly elevated in conjunction with a markedand a longer duration of treatment may be needed. In
elevation in the bone formation rate and modest im-addition, the low or inadequate calcium intake in our
provement in osteoblastic and osteoclastic activities. Thepatients might be a contributing factor, and may hinder
elevation in iPTH was not a result of hypocalcemia orthe improvement in BMD. Although dRTA has been
increased urinary calcium excretion. The relatively lowdocumented to be more severe or more frequently pre-
serum iPTH may be a protective mechanism of the bodysented in summer than in winter [11], our patients were
to prevent further reduction in bone mass when the bodyenrolled throughout the year and were treated soon after
has suffered from chronic metabolic acidosis. An eleva-the diagnosis was made. However, the timing of speci-
tion in ionized calcium induced by metabolic acidosismen collection should not have considerable effects on
might initially suppress, and subsequently the significantbone histology as it normally takes a few months to de-
elevation in serum phosphate by the treatment mightvelop significant alterations in bone histology and BMD.
restore, parathyroid hormone secretion. The associationAs reported previously, suppression in both osteoblas-
between the elevated serum iPTH level and the correc-tic and osteoclastic activities were found in our dRTA
tion of chronic acidosis in our study agrees with thepatients [3]. The bone formation rate also was markedly
finding in a previous human study, where a slight butsuppressed. Our findings suggest that the low BMD
significant reduction in serum iPTH level after a shortfound in dRTA patient resulted mainly from the reduc-
period of increased acid load to the body was found [31].tion in bone formation rather than the increased bone
However, the finding is in conflict with a few previousresorption. Although there was some degree of mineral-
studies in subjects with acute acidosis [32, 36, 37].ization defect, suggested by the significant elevation in
Regarding the pathogenesis, there is no adequate evi-osteoid volume and osteoid surface, osteomalasia was
dence to suggest whether dRTA in Thailand is an acquirednot the predominant bone lesion [3]. Therefore, the hy-
or a congenital disorder. Defects in membrane trans-pophosphatemia found initially in our study was unlikely
to be the cause of bone lesion. No relationship between porting proteins of the intercalated cell in renal collecting
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